Journal Watch · Nature Reviews Clinical Oncology · 2026

Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.

In this Review, we provide an overview of the current landscape of ADCs in gynaecological malignancies, highlighting key advances and future opportunities.

Moore KN, Yeku OO, Howitt BE et al.Nature Reviews Clinical Oncology3 min readPharma relevance 80/100

DOI: 10.1038/s41571-026-01164-9PMID: 42310472Study type: review / perspective

TL;DR

In this Review, we provide an overview of the current landscape of ADCs in gynaecological malignancies, highlighting key advances and future opportunities.

Key findings

  • In this Review, we provide an overview of the current landscape of ADCs in gynaecological malignancies, highlighting key advances and future opportunities.

What they did

Current research priorities include identifying novel targets, better understanding mechanisms of resistance and sequencing strategies, and optimal management of the toxicities of ADCs. Moreover, rational combinations could reinforce and extend the clinical potential of these agents, as has already been demonstrated with the addition of ADCs to immune checkpoint inhibitors in an effort to amplify antitumour immunity and prolong the durability of clinical responses.

Full abstract (original)

Background: Antibody-drug conjugates (ADCs) have transformed the cancer therapeutic landscape over the past two decades, profoundly shaping treatment outcomes across a wide array of indications. Three ADCs are currently approved for previously treated gynaecological cancers: mirvetuximab soravtansine for folate receptor-α-positive ovarian cancer, trastuzumab deruxtecan for solid tumours expressing HER2 (defined as a staining intensity on immunohistochemistry of 3+) and tisotumab vedotin for cervical cancer (independent of tissue factor expression).

What they did: Current research priorities include identifying novel targets, better understanding mechanisms of resistance and sequencing strategies, and optimal management of the toxicities of ADCs. Moreover, rational combinations could reinforce and extend the clinical potential of these agents, as has already been demonstrated with the addition of ADCs to immune checkpoint inhibitors in an effort to amplify antitumour immunity and prolong the durability of clinical responses.

Results & conclusions: In this Review, we provide an overview of the current landscape of ADCs in gynaecological malignancies, highlighting key advances and future opportunities.

Abstract © the authors / Nature Reviews Clinical Oncology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41571-026-01164-9 · PubMed 42310472.

Why it matters for pharma & biotech

  • Directly relevant to teams in antibody / ADC therapeutics, targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: antibody / ADC therapeutics · targeted oncology / immuno-oncology · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nature Reviews Clinical Oncology study find?

In this Review, we provide an overview of the current landscape of ADCs in gynaecological malignancies, highlighting key advances and future opportunities.

What type of study is this?

It is a review / perspective, published in Nature Reviews Clinical Oncology in 2026. Current research priorities include identifying novel targets, better understanding mechanisms of resistance and sequencing strategies, and optimal management of the toxicities of ADCs.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41571-026-01164-9. PubMed ID: 42310472. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Moore KN, Yeku OO, Howitt BE et al.. Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.. Nature Reviews Clinical Oncology (2026). DOI: 10.1038/s41571-026-01164-9.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/antibody-drug-conjugates-in-gynaecological-cancers-opportunities-and-cha-011649/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides